Company intelligence / Profile preview

Araris Biotech AG

Au / Villigen*, Zurich/Aargau*, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

Araris’ ADC candidates have demonstrated improved efficacy and tolerability in preclinical studies compared to existing ADCs. The company’s proprietary technology enables site-specific, one-step conjugation of payloads to off-the-shelf antibodies without prior engineering, resulting in stable, homogeneous ADCs with a favorable therapeutic index. No clinical results have been published as of the acquisition by Taiho Pharmaceutical[5][9].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

4 assets

ARC-02

3 more assets in the full pipeline.

Request access →

Partnerships

Taiho Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co., Ltd.[1][5][8]

Beyond the preview

Go deeper on Araris Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Araris Biotech AG.

Explore the full profile